SCHEDULE 13G/A: BlackRock Discloses 2.0% Stake in FibroBiologics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.0% beneficial ownership stake in FibroBiologics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in FibroBiologics, Inc.
- As of June 30, 2025, BlackRock, Inc. beneficially owned an aggregate of 750,898 shares of FibroBiologics, Inc. Common Stock.
- This represents 2.0% of the class of securities.
- BlackRock holds sole voting power over 748,464 shares and sole dispositive power over 750,898 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Specific BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, and BlackRock Investment Management, LLC, are identified as relevant entities, with at least one beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: This is a neutral, routine regulatory filing. The presence of a major institutional investor like BlackRock can be seen as mildly positive, but the filing itself contains no new operational or financial news about the issuer.
Positives
- The filing indicates that a major institutional investor, BlackRock, holds a position in FibroBiologics, which can be viewed as a standard portfolio allocation by a respected firm.
Industry Context
This filing is a routine disclosure of institutional ownership, reflecting BlackRock's portfolio management activities rather than specific operational or strategic trends for FibroBiologics or its industry.
Stakeholder Impact
- Primarily impacts shareholders by providing transparency on institutional ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which has been revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of the event requiring the filing of this statement, indicating the ownership threshold was met or changed. |
| 2025-07-17 | Date of filing and signature of the Schedule 13G. |
Keywords
FibroBiologics, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, 31573L105
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.